A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Feb 2021.
- 12 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Feb 2020.
- 08 Sep 2018 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History